Oxford BioDynamics (LON:OBD) Trading Up 17.2% – What’s Next?

Oxford BioDynamics Plc (LON:OBD) shares were up 17.2% during trading on Friday . The company traded as high as GBX 0.28 and last traded at GBX 0.25. 120,494,539 shares were traded during trading, an increase of 325% from the average daily volume of 28,357,795 shares. The stock had previously closed at GBX 0.22.

Analysts Set New Price Targets

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Oxford BioDynamics in a report on Wednesday, October 8th.

Oxford BioDynamics Price Performance

The company has a market cap of £10.81 million, a price-to-earnings ratio of -0.09 and a beta of 0.42. The company has a 50-day simple moving average of GBX 0.27 and a 200-day simple moving average of GBX 0.39. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.